Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

Vinorelbine cisplatin radiotherapy

"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."

Trial Locations (1)

14033

CHU CAEN, Caen

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT01839032 - Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy | Biotech Hunter | Biotech Hunter